 
    Héctor García-Calderó
Publicacions destacades
- 
                    Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic ratsAutors:Referència: Liver International 2020.
- 
                    Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.Autors:Referència: Gastroenterology 2018.
- 
                    Mitochondria-targeted antioxidant mitoquinone deactivates human and rat HSC and reduces portal hypertension in cirrhotic rats.Autors:Referència: Liver International 2017.
- 
                    Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/ResuscitationAutors:Referència: Shock 2017.
- 
                    Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic ratsAutors:Referència: Journal Of Hepatology 2016.
- 
                    Simvastatin prevents the aggravation of hepatic microvascular dysfunction caused by endotoxemia in cirrhotic ratsAutors:Referència: Hepatology 2015.
- 
                    Metformin reduces hepatic resistance and portal pressure in cirrhotic ratsAutors:Referència: American Journal Of Physiology-Gastrointestinal And Liver Physiology 2015.
- 
                    Simvastatin maintains function and viability of steatotic rat livers procured for transplantationAutors:Referència: Journal Of Hepatology 2013.
- 
                    Simvastatin maintains function and viability of steatotic livers procured for transplantationAutors:Referència: Hepatology 2012.
- 
                    Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic ratsAutors:Referència: Journal Of Hepatology 2011.
